Skip Navigation

European Heart Journal 2000 21(4):270-274; doi:10.1053/euhj.1999.1700
Copyright © 2000 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Fujita, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fujita, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Review Article

Heparin and angiogenic therapy

M. Fujitaf1

College of Medical Technology, Kyoto University, Japan

revised April 27, 1999; accepted May 5, 1999

f1 Correspondence: Professor Masatoshi Fujita, MD, College of Medical Technology, Kyoto University, 53 Kawaharacho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.

References

  1. Yoshida N, Fujita M, Yamanishi K, Miwa K. Relationship between collateral channel filling and flow grade in recipient coronary arteries in patients with stable effort angina. J Am Coll Cardiol. 1993;22:426–430[Abstract]
  2. Sasayama S, Fujita M. Recent insights into coronary collateral circulation. Circulation. 1992;85:1197–1204[Abstract/Free Full Text]
  3. Shou M, Thirumurti V, Rajanayagam S. Effect of basic fibroblast growth factor on myocardial angiogenesis in dogs with mature collateral vessels. J Am Coll Cardiol. 1997;29:1102–1106[Abstract]
  4. Nolewajka AJ, Kostuk WJ, Rechnitzer PA, Cunningham DA. Exercise and human collateralization: an angiographic and scintigraphic assessment. Circulation. 1979;60:114–121[Abstract/Free Full Text]
  5. Ehsani AA, Heath GW, Hagberg JM, Sobel BE, Holloszy JO. Effects of 12 months of intense exercise training on ischemic ST-segment depression in patients with coronary artery disease. Circulation. 1981;64:1116–1124[Abstract/Free Full Text]
  6. Hockel M, Schlenger K, Doctrow S, Kissel T, Vaupel P. Therapeutic angiogenesis. Arch Surg. 1993;128:423–429[Abstract]
  7. Fujita M, Sasayama S, Asanoi H, Nakajima H, Sakai O, Ohno A. Improvement of treadmill capacity and collateral circulation as a result of exercise with heparin pretreatment in patients with effort angina. Circulation. 1988;77:1022–1029[Abstract/Free Full Text]
  8. Schuler G, Schlierf G, Wirth A. Low fat diet and regular supervised physical exercise in patients with symptomatic coronary artery disease: reduction of stress induced myocardial ischaemia. Circulation. 1988;77:172–181[Abstract/Free Full Text]
  9. Todd IC, Bradnum MS, Cooke MBD, Ballantyne D. Effects of daily high intensity exercise on myocardial perfusion in angina pectoris. Am J Cardiol. 1991;68:1593–1599[CrossRef][ISI][Medline]
  10. Yanagisawa-Miwa A, Uchida A, Nakamura F. Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science. 1992;257:1401–1403[Abstract/Free Full Text]
  11. Harada K, Friedman M, Lopez JJ. Vascular endothelial growth factor administration in chronic myocardial ischemia. Am J Physiol. 1996;270:H1791–1802
  12. Schumacher B, Pecher P, von Specht B, Stegmann T. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation. 1998;97:645–650[Abstract/Free Full Text]
  13. Sellke FW, Laham RJ, Edelman ER, Pearlman JD, Simons M. Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results. Ann Thorac Surg. 1998;65:1540–1544[Abstract/Free Full Text]
  14. Rodén L. Highlights in the history of heparin. Lane DA, Lindahl U. Heparin, Vol. 1. London: Edward Arnold; 1989. p. 1–23
  15. Taylor S, Folkman J. Protamine is an inhibitor of angiogenesis. Nature. 1982;297:307–312[CrossRef][Medline]
  16. Thornton SC, Mueller SN, Levine EM. Human endothelial cells: use of heparin in cloning and long-term serial cultivation. Science. 1983;222:623–625[Abstract/Free Full Text]
  17. Schreiber AB, Kenney J, Kowalski WJ. Interaction of endothelial cell growth factor with heparin: characterization by receptor and antibody recognition. Proc Natl Acad Sci U S A. 1985;82:6138–6142[Abstract/Free Full Text]
  18. Gospodarowicz D, Cheng J. Heparin protects basic and acidic FGF from inactivation. J Cell Physiol. 1986;128:475–484[CrossRef][ISI][Medline]
  19. Folkman J, Klagsbrun M. Angiogenic factors. Science. 1987;235:442–447[Abstract/Free Full Text]
  20. Fujita M, Mikuniya A, Takahashi M, Gaddis R, Hartley J, McKown D. Acceleration of coronary collateral development by heparin in conscious dogs. Jpn Circ J. 1987;51:395–402[Medline]
  21. Unger EF, Sheffield CD, Epstein SE. Heparin promotes the formation of extracardiac to coronary anastomoses in a canine model. AM J Physiol. 1991;260:H1625–1634
  22. Carroll SM, White FC, Roth DM, Bloor CM. Heparin accelerates coronary collateral development in a porcine model of coronary artery occlusion. Circulation. 1993;88:198–207[Abstract/Free Full Text]
  23. Quyyumi AA, Diodati JG, Lakatos E. Angiogenic effects of low molecular weight heparin in patients with stable coronary artery disease; a pilot study. J Am Coll Cardiol. 1993;22:635–641[Abstract]
  24. Fujita M, Sasayama S, Kato K. Prospective, randomized, placebo-controlled, double-blind, multicenter study of exercise with enoxaparin pretreatment for stable-effort angina. Am Heart J. 1995;129:535–541[CrossRef][ISI][Medline]
  25. Gagliardi JA, Prado NG, Marino JC. Exercise training and heparin pretreatment in patients with coronary artery disease. Am Heart J. 1996;132:946–951[CrossRef][ISI][Medline]
  26. Rebuck JW, Hudson JM, Priest RJ, Barth CL. Basophilic granulocytes in inflammatory tissues of man. Ann N Y Acad Sci. 1962;103:409–426[CrossRef]
  27. Azizkhan RG, Azizkhan JC, Zetter BR, Folkman J. Mast cell heparin stimulates migration of capillary endothelial cells in vitro. J Exp Med. 1980;152:931–944[Abstract/Free Full Text]
  28. Shing Y, Folkman J, Sullivan R, Butterfield C, Murray J, Klagsburn M. Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor. Science. 1984;223:1296–1299[Abstract/Free Full Text]
  29. Folkman J, Klagsbrun M, Sasse J, Wadzinski M, Ingber D, Vlodavsky I. A heparin-binding angiogenic protein-basic fibroblast growth factor is stored within basement membrane. Am J Pathol. 1988;130:393–400[Abstract]
  30. Vlodavsky I, Fuks Z, Ishai-Michaeli R. Extracellular matrix-resident basic fibroblast growth factor: implication for the control of angiogenesis. J Cell Biochem. 1991;45:167–176[CrossRef][ISI][Medline]
  31. Ornitz DM, Yayon A, Flanagan JG, Svahn CM, Levi E, Leder P. Heparin in required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells. Mol Cell Biol. 1992;12:240–247[Abstract/Free Full Text]
  32. Mascarelli F, Fuhrmann G, Courtois Y. aFGF binding to low and high affinity receptors induces both aFGF and aFGF receptors dimerization. Growth Factors. 1993;8:211–233[ISI][Medline]
  33. Spivak-Kroizman T, Lemmon MA, Dikic I. Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation. Cell. 1994;79:1015–1024[CrossRef][ISI][Medline]
  34. Franklin D, McKown D, McKown M, Hartley J, Caldwell M. Development and regression of coronary collaterals induced by repeated, reversible ischemia in dogs. Fed Proc. 1981;40:339
  35. Fujita M, McKown DP, McKown MD, Hartley J, Franklin D. Evaluation of coronary collateral development by regional myocardial function and reactive hyperaemia. Cardiovasc Res. 1987;21:377–384[ISI][Medline]
  36. Unger EF, Sheffield CD, Epstein SE. Creation of anastomoses between an extracardiac artery and the coronary circulation. Circulation. 1990;82:1449–1466[Abstract/Free Full Text]
  37. Mohri M, Tomoike H, Noma M, Inoue T, Hisano K, Nakamura M. Duration of ischemia is vital for collateral development: repeated brief coronary artery occlusion in conscious dogs. Circ Res. 1989;64:287–296[Abstract/Free Full Text]
  38. Chilian WM, Mass HJ, Williams SE, Layne SM, Smith EE, Scheel KW. Microvascular occlusions promote coronary collateral growth. Am J Physiol. 1990;258:H1103–1111
  39. Schaper W. Tangential wall stress as a molding force in the development of collateral vessels in the canine heart. Experientia. 1967;23:595–596[CrossRef][ISI][Medline]
  40. Symons JD, Pitsillides KF, Longhurst JC. Chronic reduction of myocardial ischemia does not attenuate coronary collateral development in miniswine. Circulation. 1992;86:660–671[Abstract/Free Full Text]
  41. Kumar S, Shahabuddin S, Haboubi N. Angiogenesis factor from human myocardial infarcts. Lancet. 1983;2:364–368[ISI][Medline]
  42. Fujita M, Ikemoto M, Kishishita M. Elevated basic fibroblast growth factor in pericardial fluid of patients with unstable angina. Circulation. 1996;94:610–613[Abstract/Free Full Text]
  43. Fujita M, Yamanishi K, Hirai T, Ohno A, Miwa K, Sasayama S. Comparative effect of heparin treatment with and without strenuous exercise on treadmill capacity in patients with stable effort angina. Am Heart J. 1991;122:453–457[CrossRef][ISI][Medline]
  44. Ejiri M, Fujita M, Miwa K. Effects of heparin treatment on collateral development and regional myocardial function in acute myocardial infarction. Am Heart J. 1990;119:248–253[CrossRef][ISI][Medline]
  45. Fujita M, Miwa K, Nozawa T, Asanoi H, Futatsuya R, Sasayama S. Long-term efficacy of heparin exercise treatment for patients with chronic effort angina: evaluation by exercise T1-201 myocardial scintigraphy. Int J Cardiol. 1993;40:51–56[CrossRef][ISI][Medline]
  46. Tanaka T, Fujita M, Nakae I. Improvement of exercise capacity by sarpogrelate as a result of augmented collateral circulation in patients with effort angina. J Am Coll Cardiol. 1998;32:1982–1986[Abstract/Free Full Text]
  47. Kern MJ, Piek JJ, Aguirre FV, Bach RG, Caracciolo EA, Donohue TJ. Collateral flow velocity alterations in the supply and receiving coronary arteries during angioplasty for total coronary occlusion. Cathet Cardiovasc Diagn. 1995;34:167–174[ISI][Medline]
  48. Probst P, Zangl W, Pachinger O. Relation of coronary arterial occlusion pressure during percutaneous transluminal coronary angioplasty to presence of collaterals. Am J Cardiol. 1985;55:1264–1269[CrossRef][ISI][Medline]
  49. Schaper W, Ito WD. Molecular mechanisms of coronary collateral vessel growth. Circ Res. 1996;79:911–919[Free Full Text]
  50. Ito WD, Arras M, Winkler B, Scholz D, Schaper J, Schaper W. Monocyte chemotactic protein-1 increases collateral and peripheral conductance after femoral artery occlusion. Circ Res. 1997;80:829–837[Abstract/Free Full Text]
  51. Lawson WE, Hui JC, Soroff HS. Efficacy of enhanced external counterpulsation in the treatment of angina pectoris. Am J Cardiol. 1992;70:859–862[CrossRef][ISI][Medline]
  52. Solignac A, Ferguson RJ, Bourassa MG. External counterpulsation: coronary hemodynamics and use in treatment of patients with stable angina pectoris. Cathet Cardiovasc Diag. 1977;3:37–45[ISI][Medline]
  53. Chou TM, Arora RR, Jain D. Importance of the number of patent vessels in the benefit seen with enhanced external counterpulsation in chronic angina: results of the MUST-EECP trial. Circulation. 1998;98:I–350

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 HeartHome page
M Fujita and K Tambara
Recent insights into human coronary collateral development
Heart, March 1, 2004; 90(3): 246 - 250.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
M. Kalani, J. Apelqvist, M. Blomback, K. Brismar, B. Eliasson, J. W. Eriksson, B. Fagrell, A. Hamsten, O. Torffvit, and G. Jorneskog
Effect of Dalteparin on Healing of Chronic Foot Ulcers in Diabetic Patients With Peripheral Arterial Occlusive Disease: A prospective, randomized, double-blind, placebo-controlled study
Diabetes Care, September 1, 2003; 26(9): 2575 - 2580.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
M. Voskuil, N. van Royen, I. E. Hoefer, R. Seidler, B. D. Guth, C. Bode, W. Schaper, J. J. Piek, and I. R. Buschmann
Modulation of collateral artery growth in a porcine hindlimb ligation model using MCP-1
Am J Physiol Heart Circ Physiol, April 1, 2003; 284(4): H1422 - H1428.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
N. van Royen, J. J. Piek, I. Buschmann, I. Hoefer, M. Voskuil, and W. Schaper
Stimulation of arteriogenesis; a new concept for the treatment of arterial occlusive disease
Cardiovasc Res, February 16, 2001; 49(3): 543 - 553.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Fujita, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fujita, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?